Eli Lilly reports Jaypirca benefit in Phase 3 CLL study, cutting risk of progression or death by 45%

Eli Lilly (NYSE: LLY) said results from a Phase 3 trial of its cancer drug Jaypirca (pirtobrutinib) showed a sizable reduction in the risk of disease progression or death when the BTK inhibitor was added to a time-limited treatment backbone for patients with previously treated CLL and SLL.

In the BRUIN CLL-322 study, Lilly reported that adding Jaypirca to a regimen that includes venetoclax on a time-limited schedule and rituximab reduced the risk of disease progression or death by 45%, according to the company’s announcement.

Jaypirca is a non-covalent Bruton tyrosine kinase (BTK) inhibitor. BTK inhibitors are designed to disrupt indicating pathways that help certain B-cell cancers survive. Lilly’s choice of a non-covalent approach is aimed at broadening activity, including among patients who may have previously received BTK-targeted therapies, though the announcement does not provide those subgroup details in the material available here.

The company also framed the study in the context of CLL/SLL treatment, where clinicians have increasingly used fixed-duration combination regimens to pursue deep remissions while limiting long-term exposure to therapy. Venetoclax, in combination with antibodies such as rituximab, has been used to create time-limited courses in selected patients, and Lilly’s Phase 3 evaluation centers on improving the effectiveness of that approach by adding Jaypirca.

For investors and clinicians, the headline figure of a 45% risk reduction is potentially significant because it suggests an added layer of benefit from combining a newer BTK inhibitor with a well-established venetoclax-based foundation. However, the announcement coverage available here does not include the underlying statistical measures beyond the reported risk reduction, such as hazard ratio confidence intervals, exact p-values, or whether the trial met any secondary endpoints.

The company’s update, as reflected in the published market report, also does not spell out key clinical and safety details in the available text, including median progression-free survival timing, overall survival data, response rate changes, or rates of adverse events leading to dose changes or discontinuation. Those elements often matter as much as the primary endpoint when regulators and physicians weigh whether a combination should become a standard option.

Still, the Phase 3 label is notable. BRUIN CLL-322 is positioned as a late-stage test of pirtobrutinib in a specific treatment strategy, and the study’s design suggests Lilly is pursuing a broader role for Jaypirca beyond monotherapy, potentially in combination regimens that target multiple survival pathways in CLL and SLL.

What to watch next is what Lilly and regulators choose to disclose as the program advances: full statistical tables, safety findings, subgroup outcomes by prior therapy history, and whether the combination produces durable responses that justify its added complexity. A next readout could come in the form of a conference presentation or a regulatory filing if the results support further development and potential approval discussions.